Trial Profile
A prospective study to evaluate efficacy and safety of levonorgestral intrauterine device (Mirena) combined with gonadotropin-releasing hormone agonist (Zoladex) in female patients with grade 1 endometrial carcinoma and the levonorgestrel monotherapy in female patients with complex atypical hyperplasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
- Indications Adenocarcinoma; Atypical endometrial hyperplasia; Endometrial cancer; Pregnancy
- Focus Therapeutic Use
- 15 Jan 2021 Primary endpoint has been met. (complete response rate)
- 15 Jan 2021 Results published in the Gynecologic Oncology
- 28 Apr 2016 New trial record